A systematic review and economic model of the effectiveness and ...

138
References
113. MTA Cooperative Group. National Institute of
Mental Health Multimodal Treatment Study of
ADHD follow-up: 24-month outcomes of treatment
strategies for attention-deficit/hyperactivity
disorder. Pediatrics 2004;113:754–61.
114. Rapport MD, Moffitt C. Attention
deficit/hyperactivity disorder and
methylphenidate. A review of height/weight,
cardiovascular, and somatic complaint side effects.
Clin Psychol Rev 2002;22:1107–31.
115. Drummond M, O’Brien B, Stoddart G, Torrance
G. Methods for the economic evaluation of health care
programmes. 2nd ed. Oxford: Oxford Medical
Publications; 1997.
116. Markwardt FC. Peabody Individual Achievement Test
(PIAT). Circle Pines, MN: American Guidance
Service; 1998.
117. Pelham WE, Bender ME, Caddell J, Booth S,
Moorer SH. Methylphenidate and children with
attention deficit disorder. Arch Gen Psychiatry
1985;42:948–52.
118. Conners CK, Epstein JN, March JS, Angold A,
Wells KC, Klaric J, et al. Multimodal treatment of
ADHD in the MTA: an alternative outcome
analysis. J Am Acad Child Adolesc Psychiatry
2001;40:159–67.
119. Rosser R, Cottee M, Rabin R, Selai C. Index of
health related quality of life. In Hopkins A, editor.
Measures of the quality of life. London: Royal College
of Doctors; 1992.
120. Landgraf J, Abetz L, Ware J. The Child Health
Questionnaire user’s manual. Boston, MA: HealthAct;
1999.
121. Zwi M, Ramchandani P, Joughin C. Evidence and
belief in ADHD. BMJ 2000;321:975–6.
122. Dolan P, Gudex C, Kind P, Williams A. A social tariff
for the EurQol: results from a UK general population
survey. York: Centre for Health Economics,
University of York; 1995.
123. Gilmore A, Milne R. Methylphenidate in children
with hyperactivity: review and cost–utility analysis.
Pharmacoepidemiol Drug Saf 2001;10:85–94.
124. Gilmore A, Best L, Milne R. Methylphenidate in
children with hyperactivity. Report No. 78.
Southampton: Wessex Institute for Health
Research and Development; 1998.
125. Matza LS, Secnik K, Rentz AM, Mannix S,
Revicki DA, Sallee FR. Development and
assessment of health state utilities for attention
deficit/hyperactivity disorder in children using
parent proxy report. Value Health 2003;6:697–8.
126. Zupancic JAF, Miller A, Raina P, Lee SK,
Klassen A, Olsen L. A review of therapies for attention
deficit/hyperactivity disorder. Ottawa: Canadian
Coordinating Office for Health Technology
Assessment; 1998.
127. Shukla VK, Otten N. Assessment of attention
deficit/hyperactivity disorder therapy: a Canadian
perspective. Ottawa: Canadian Coordinating Office
for Health Technology Assessment (CCOHTA);
1999. URL: http://www.ccohta.ca/
128. Marchetti A, Magar R, Lau H, Murphy EL,
Jensen PS, Conners CK, et al. Pharmacotherapies
for attention-deficit/hyperactivity disorder:
expected-cost analysis. Clin Ther 2001;23:1904–21.
129. Vanoverbeke N, Annemans L, Ingham M,
Adriaenssen I. A cost analysis of the management
of attention-deficit/hyperactivity disorder (ADHD)
in children in the UK. J Med Econ 2003;6:79–94.
130. Barkley RA. Child behaviour rating scales and
checklists. In Rutter M, Tuma AH, Lann IS,
editors. Assessment and diagnosis in child
psychopathology. New York: Guildford Press; 1988.
131. Monthly index of medical specialities (MIMS) [August].
London: Haymarket Medical Publications, 1997.
132. Foster N. Comorbidity as a moderator of costeffectiveness.
York: University of York; 2004.
133. Swanson JM, Kraemer HC, Hinshaw SP,
Arnold LE, Conners CK, Abikoff HB, et al. Clinical
relevance of the primary findings of the MTA:
success rates based on severity of ADHD and ODD
symptoms at the end of treatment. J Am Acad Child
Adolesc Psychiatry 2001;40:168–79.
134. National Institute for Clinical Excellence (NICE).
Methylphenidate (Ritalin, Equasym) for attention
deficit/hyperactivity disorder (ADHD) in childhood.
London: NICE; 2000. URL:
http://www.nice.org.uk/article.asp?a=11667
135. Netten A, Curtis L. Unit costs of health and social
care. Canterbury: Personal Social Services Research
Unit (PSSRU), University of Kent; 2003. URL:
www.pssru.ac.uk
136. Coghill D, Spender Q, Barton J, Hollis C, Yuen C,
Cleemput I, et al. Measuring quality of life in
children with attention-deficit-hyperactivitydisorder
in the United Kingdom. In 16th World
Congress of the International Association of Child and
Adolescent Psychiatry and Allied Professions
(IACAPAP), 23–26 August 2004, Berlin. URL:
http://www.iacapap-berlin.de/guest/?MIval=
AbstractView&ABSID=4112
137. Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–89.
138. Kauffman RE, Smith-Wright D, Reese CA,
Simpson R, Jones F. Medication compliance in
hyperactive children. Pediatr Pharmacol
1981;1:231–7.
139. Dirksen SJ, D’Imperio JM, Birdsall D, Hatch SJ.
A postmarketing clinical experience study of
Metadate CD. Curr Med Res Opin 2002;18:371–80.